 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AngioDynamics (NASDAQ:ANGO - Get Free Report) was upgraded by stock analysts at Oppenheimer from a "market perform" rating to an "outperform" rating in a report released on Friday, Marketbeat Ratings...

Oppenheimer Upgrades AngioDynamics (NASDAQ:ANGO) to "Outperform"

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Oppenheimer gets more bullish on AngioDynamics, upgrades shares

ANGO reports solid revenue growth with strategic advancements, despite facing margin pressures and a significant GAAP net loss.Related Stocks: ANGO...

AngioDynamics Inc (ANGO) Q3 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ...

Q3 2024 AngioDynamics Inc Earnings Call Transcript

ANGO's Earnings Miss Analyst Projections Despite Revenue GrowthRelated Stocks: ANGO...

AngioDynamics Inc (ANGO) Posts Q3 Fiscal 2024 Results: A Mixed Performance Amidst Asset Divestiture

AngioDynamics reports Q3 adjusted EPS (16c), consensus (13c)

AngioDynamics Non-GAAP EPS of -$0.16, revenue of $65.97M...

AngioDynamics Non-GAAP EPS of -$0.16, revenue of $65.97M

AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights Completed the sale of its PICC and Midline product portfolios to Spectrum Vascular on February 15, 2024 Discontinued its...

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the bodys vascular system, expanding cancer treatment options...

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript...

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

AngioDynamics, Inc. operates as a medical device company, which engages in the development, manufacturing and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It operates through the Med Tech and Med Device segments. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.

Volume (M)	199,105.00
52-Wk High	$11.38
52-Wk Low	$5.26

ANGO Angiodynamic Inc

About

Feed

News

Sentiment

Earnings

Fundamentals